Risk, Prevalence, and Progression of Glaucoma in Eyes With Age-Related Macular Degeneration Treated With Intravitreal Anti–Vascular Endothelial Growth Factor Injections
American Journal of Ophthalmology, ISSN: 0002-9394, Vol: 243, Page: 98-108
2022
- 6Citations
- 15Captures
- 1Mentions
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations6
- Citation Indexes6
- Captures15
- Readers15
- 15
- Mentions1
- News Mentions1
- 1
Most Recent News
Data on Age-Related Macular Degeneration Reported by Researchers at Mayo Clinic (Risk, Prevalence, and Progression of Glaucoma In Eyes With Age-related Macular Degeneration Treated With Intravitreal Anti-vascular Endothelial Growth Factor ...)
2022 NOV 09 (NewsRx) -- By a News Reporter-Staff News Editor at Angiogenesis Daily -- Research findings on Eye Diseases and Conditions - Age-Related Macular
Article Description
To examine the risk, prevalence, and progression of glaucoma development in age-related macular degeneration (AMD) eyes receiving intravitreal anti–vascular endothelial growth factor (anti-VEGF) injections compared to controls. Retrospective clinical cohort study. Retrospective review of eyes receiving intravitreal anti-VEGF injections from January 1, 2004, to December 31, 2013, for exudative AMD. Age- and sex-matched control groups of eyes included eyes with nonexudative AMD (NEAMD) and no AMD. Eyes with a diagnosis of glaucoma or glaucoma suspect were reviewed for injection details, type and date of glaucoma diagnosis, glaucoma treatments, standard automated perimetry (SAP), and spectral domain optical coherence tomography (SD-OCT). Qualitative progression was determined by indication of glaucoma progression in provider notes. Quantitative progression was assessed based on change in mean deviation (MD) on SAP, retinal nerve fiber layer thickness on SD-OCT, and intraocular pressure (IOP). There were 707 eyes of 504 patients treated with anti-VEGF injections and 1008 eyes in the NEAMD and no-AMD cohorts. There was no difference in glaucoma or suspect prevalence at initial presentation between eyes treated with injections and NEAMD (6.9% vs 9.7%, P = .22) or no-AMD controls (vs 8.5%, P = .55). There was no difference in cumulative 5-year probability of new glaucoma diagnosis after anti-VEGF injections compared to NEAMD (1.9% vs 1.0%, P = .69) or no-AMD controls (vs 1.6%, P = .88). There was no difference in qualitative progression of glaucoma in the injection cohort vs NEAMD ( P = .19) or no-AMD controls ( P = .61). The rate of MD change in injection eyes was similar to NEAMD eyes ( P = .74) but greater than no-AMD eyes ( P = .02). Eyes receiving injections required more topical glaucoma medications compared with NEAMD ( P = .03) and more glaucoma laser treatments compared with no-AMD controls ( P = .009). Eyes receiving injections did not require more frequent incisional glaucoma surgery compared with NEAMD (21.0% vs 15.0%, P = .95) or no-AMD controls (vs 10.0%, P = .10). Eyes treated with intravitreal anti-VEGF injections for exudative AMD did not have increased risk of developing glaucoma compared with controls. Of those with a glaucoma diagnosis, exudative AMD eyes receiving injections required a greater number of topical glaucoma medications compared with NEAMD eyes and had a greater rate of MD loss than no-AMD controls.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S0002939422002926; http://dx.doi.org/10.1016/j.ajo.2022.07.025; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85137282161&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/35932820; https://linkinghub.elsevier.com/retrieve/pii/S0002939422002926; https://dx.doi.org/10.1016/j.ajo.2022.07.025
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know